GlassScriptPhysician profile
Raymond C Lackore
NPI 1447336094
$728.07
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $105 · 2021: $241 · 2022: $79.77.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $219.48 | 2019-2022 | |
| Minerva Surgical, INC | $194.68 | 2019-2020 | |
| Myovant Sciences INC. | $124.41 | 2021 | |
| Organon LLC | $43.05 | 2021-2022 | |
| Covidien LP | $26.33 | 2020 | |
| Exeltis, USA INC. | $20.04 | 2021 | |
| Medtronic USA, INC. | $19.25 | 2020 | |
| Avion Pharmaceuticals | $18.79 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.79 | 2022 | |
| Merck Sharp & Dohme LLC | $15.87 | 2019 | |
| Evofem Biosciences, INC. | $15.25 | 2021 | |
| Therapeuticsmd, INC. | $13.13 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Lackore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.